There is limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer (BC), especially in patients treated with endocrine therapy (ET) + CDK 4/6 inhibitors.
Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy
Lambertini, Matteo;
2021-01-01
Abstract
There is limited data regarding the impact of body mass index (BMI) on outcomes in advanced breast cancer (BC), especially in patients treated with endocrine therapy (ET) + CDK 4/6 inhibitors.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
djaa116.pdf
accesso chiuso
Tipologia:
Documento in versione editoriale
Dimensione
1.31 MB
Formato
Adobe PDF
|
1.31 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
